Abstract Search

ey0016.5-5 | New Insight into Rare Skeletal Disorders | ESPEYB16

5.5. Osteoporosis and skeletal dysplasia caused by pathogenic variants in SGMS2

M Pekkinen , PA Terhal , LD Botto , P Henning , RE Makitie , P Roschger , A Jain , M Kol , MA Kjellberg , EP Paschalis , K van Gassen , M Murray , P Bayrak-Toydemir , MK Magnusson , J Jans , M Kausar , JC Carey , P Somerharju , UH Lerner , VM Olkkonen , K Klaushofer , JC Holthuis , O Makitie

Abstract: JCI Insight. 2019; Apr 4;4(7).In brief: This study describes a novel autosomal dominant form of primary osteoporosis caused by SGMS2 mutations in six families. A recurrent mutation p.Arg50* led to primary osteoporosis in four families, whereas missense mutations p.Ile62Ser and p.Met64Arg caused a much more severe bone phenotype with spondylometaphyseal d...

0 shares

ey0015.11-12 | Hungry fat cells | ESPEYB15

11.12 Asprosin is a centrally acting orexigenic hormone

C Duerrschmid , Y He , C Wang , C Li , JC Bournat , C Romere , PK Saha , ME Lee , KJ Phillips , M Jain , P Jia , Z Zhao , M Farias , Q Wu , DM Milewicz , VR Sutton , DD Moore , NF Butte , MJ Krashes , Y Xu , AR Chopra

To read the full abstract: Nat Med. 2017 Dec; 23(12): 1444–1453This study highlights the importance of asprosin in the regulation of appetite. This peptide hormone was first described by Romere et al. in 2016 (1), who reported 2 patients with neonatal progeroid syndrome (NPS) due to truncating heterozygous mutations in the fibrillin-gene (FBN1). The FBN1 gene encodes profibrillin wh...

0 shares

ESPE Yearbook of Paediatric Endocrinology

5.5. Osteoporosis and skeletal dysplasia caused by pathogenic variants in SGMS2

11.12 Asprosin is a centrally acting orexigenic hormone

BiosciAbstracts